The IL-6/IL-6R signaling pathway is the main mediator of CRS occurrence; therefore, targeting IL-6 for anticytokine therapy is an effective treatment method to mitigate CRS symptoms. This evidence concerns the gene IL6R and congenital rubella syndrome.